.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) significantly impact the health of older adults globally. Researchers recently presented promising results for VXB-241, a bivalent RSV hMPV vaccine candidate, in a Phase 1 clinical trial. This study evaluates the safety and immunogenicity of this unadjuvanted liquid formulation designed to simplify vaccination schedules.
The ongoing randomised trial involved older adults aged 60 to 83 years. Participants received varying doses of VXB-241, ranging from 60 μg to 480 μg. Investigators compared these groups against a placebo and the licensed AS01-adjuvanted RSV vaccine. Specifically, the interim analysis focused on safety and antibody responses one month after injection.
Data showed that VXB-241 induced robust neutralising antibody titres against RSV-A, RSV-B, hMPV-A, and hMPV-B. Furthermore, the 240 μg dose level yielded geometric mean fold increases that compared favourably with the active control. For instance, RSV-A and RSV-B responses were at least as high as those seen with the licensed adjuvanted vaccine. Additionally, VXB-241 elicited strong responses against hMPV, whereas the active control showed negligible effects against this virus.
Regarding safety, the candidate vaccine displayed a clinically acceptable profile. While solicited adverse events occurred more frequently in the vaccine groups than in the placebo group, most reactions were mild and transient. Moreover, no safety signals emerged during this interim analysis. Consequently, these findings support the continued clinical development of VXB-241 as a potential tool for protecting older populations.
VXB-241 is a bivalent vaccine candidate that targets both RSV and hMPV. It utilizes a recombinant glycoprotein F-molecular clamp technology to stabilise viral antigens in their pre-fusion state, which enhances the immune response.
Yes, the 1-month interim analysis of the Phase 1 trial reported a clinically acceptable safety and reactogenicity profile. Most adverse events were mild and no significant safety signals emerged among the older adult participants during the study period.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition or vaccination. Refer to the latest local and national guidelines for clinical practice.
References
Della Cioppa G et al. Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo- and active-controlled, phase 1 trial. Vaccine. 2026 Jun 01. doi: undefined. PMID: 42224773.
ClinicalTrials.gov. A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults. NCT06556147.
Vicebio Ltd. Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine. PR Newswire. November 21, 2024.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
VXB-241, a bivalent RSV and hMPV vaccine candidate, demonstrated high immunogenicity and a favorable safety profile in a Phase 1 trial for older adults....
last month
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
